[1] 王宇静, 熊惠娟, 吴莎莎, 等. 铂类抗癌药物的研究现状与进展[J]. 湖北科技学院学报:医学版, 2020, 34(3):270-273.
[2] 司秀文, 宋向芹, 燕晶晶, 等. 妇科肿瘤治疗中铂类抗癌药物的应用研究[J]. 中国全科医学, 2021, 24(S1):90-92.
[3] 林杰, 谢筱筱, 虞相博, 等. OCT4在顺铂治疗睾丸胚胎癌中的作用[J]. 现代免疫学, 2020, 40(6):446-453.
[4] 苏霁清. 白蛋白结合型紫杉醇联合奥沙利铂和氟尿嘧啶治疗胃癌的临床疗效[J]. 临床合理用药杂志, 2021, 14(24):51-53.
[5] 李海燕. 铂类抗癌药物作用靶点及耐药机制的研究进展[J]. 天津药学, 2018, 30(5):62-66.
[6] 唐凤娇. 不同铂类腹腔热灌注化疗治疗腹膜转移胃腺癌的药代动力学及疗效分析[D]. 长春:吉林大学, 2015.
[7] 赵伟曼, 董智勇, 时宗芬, 等. 下调miR-205-5p增强鼻咽癌细胞HNE1/DDP对顺铂诱导凋亡的敏感性[J]. 药学学报, 2019, 54(7):1200-1206.
[8] XIAN C H, CHEN H L, XIONG F, et al. Platinum-based chemotherapy via nanocarriers and co-delivery of multiple drugs[J]. Biomater Sci, 2021, 9(18):6023-6036.
[9] 周建平. 纳米技术在药物递送中的应用与展望[J]. 中国药科大学学报, 2020, 51(4):379-382.
[10] JUN W. The enhanced permeability and retention (EPR) effect:the significance of the concept and methods to enhance its application[J]. J Pers Med, 2021, 11(8):771.
[11] 杨贵兰, 李文军, 王春华. 靶向脂质体的研究进展[J]. 药学研究, 2020, 39(5):289-293, 307.
[12] 王浩. 盐酸多柔比星脂质体注射液的纳米药代动力学研究[D]. 长春:吉林大学, 2016.
[13] KHOKHAR A R, WRIGHT K, SIDDIK Z H, et al. Organ distribution and tumor uptake of liposome entrapped Cis-bis-neodecanoato trans-R, R-1, 2 diaminocyclohexane platinum (Ⅱ) administered intravenously and into the proper hepatic artery[J]. Cancer Chemother Pharmacol, 1988, 22(3):223-227.
[14] DRAGOVICH T, MENDELSON D, KURTIN S, et al. A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer[J]. Cancer Chemother Pharmacol, 2006, 58(6):759-764.
[15] MORI A, WU S P, HAN I, et al. In vivo antitumor activity of Cis-bis-neodecanoato-trans-R, R-l, 2-diaminocyclohexane platinum(Ⅱ) formulated in long-circulating liposomes[J]. Cancer Chemother Pharmacol, 1996, 37(5):435-444.
[16] NEWMAN M S, COLBERN G T, WORKING P K, et al. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice[J]. Cancer Chemother Pharmacol, 1999, 43(1):1-7.
[17] SEETHARAMU N, KIM E, HOCHSTER H, et al. Phase Ⅱ study of liposomal cisplatin (SPI-77) in platinum-sensitive recurrences of ovarian cancer[J]. Anticancer Res, 2010, 30(2):541-545.
[18] STATHOPOULOS G P, BOULIKAS T. Lipoplatin formulation review article[J]. J Drug Deliv, 2012, 2012:581363.
[19] FANTINI M, GIANNI L, SANTELMO C, et al. Lipoplatin treatment in lung and breast cancer[J]. Chemother Res Pract, 2011, 2011:125192.
[20] STATHOPOULOS G P, ANTONIOU D, DIMITROULIS J, et al. Comparison of liposomal cisplatin versus cisplatin in non-squamous cell non-small-cell lung cancer[J]. Cancer Chemother Pharmacol, 2011, 68(4):945-950.
[21] STATHOPOULOS G P, BOULIKAS T, KOURVETARIS A, et al. Liposomal oxaliplatin in the treatment of advanced cancer:a phase I study[J]. Anticancer Res, 2006, 26(2b):1489-1493.
[22] TIPPAYAMONTRI T, KOTB R, SANCHE L, et al. New therapeutic possibilities of combined treatment of radiotherapy with oxaliplatin and its liposomal formulation, LipoxalTM, in rectal cancer using xenograft in nude mice[J]. Anticancer Res, 2014, 34(10):5303-5312.
[23] DE JONGE M J, SLINGERLAND M, LOOS W J, et al. Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation[J]. Eur J Cancer, 2010, 46(16):3016-3021.
[24] ØSTREM R G, PARHAMIFAR L, POURHASSAN H, et al. Secretory phospholipase A2 responsive liposomes exhibit a potent anti-neoplastic effect in vitro, but induce unforeseen severe toxicity in vivo[J]. J Control Release, 2017, 262:212-221.
[25] SHAFEI A, EL-BAKLY W, SOBHY A, et al. A review on the efficacy and toxicity of different doxorubicin nanoparticles for targeted therapy in metastatic breast cancer[J]. Biomed Pharmacother, 2017, 95:1209-1218. |
